Valneva SE ADR (VALN)
Valneva SE ADR (NASDAQ: VALN) is a depositary receipt linked to Valneva SE, a specialty vaccine company focused on developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases with unmet medical needs. The company’s marketed products include IXIARO for Japanese encephalitis, DUKORAL for prevention of certain forms of diarrhea, and IXCHIQ/VLA1553 for prevention of chikungunya disease. Valneva also has a development pipeline that includes candidates for Lyme disease, shigellosis, Zika virus, human metapneumovirus, primary symptomatic clostridium difficile infection, and Epstein-Barr virus. Its products are sold in the United States, Canada, Germany, Austria, the Nordics, the United Kingdom, France, other European markets, and internationally. Valneva SE was founded in 1998 and is based in Saint-Herblain, France.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-VALN
|
$8.01
|
22.2% Upside
|
Undervalued
|
$12.25
|
86.7% Upside
|
Bargain
|
Fair
|
0.0%
|
November 12, 2026
|
6.5x
|
3.7x
|
609.9 M
|
707.7 M
|
28.0%
|
82.9%
|
-3.1
|
36.8%
|
